文献速递消化道肿瘤与早癌炎症性肠病

GNAI1和GNAI3通过阻断IL6信号并下调GNAI2表达减少小鼠结肠炎相关肿瘤发生

GNAI1 and GNAI3 Reduce Colitis-Associated Tumorigenesis in Mice by Blocking IL6 Signaling and Down-regulating Expression of GNAI2.
PubMed 文献 · Gastroenterology · 2019-03-02

该研究在小鼠模型和患者组织中探究GNAI1、GNAI2、GNAI3及IL6信号在结肠炎相关癌症(CAC)中的作用。GNAI1;3双敲除小鼠经DSS+AOM后结肠肿瘤显著多于对照,伴NF-κB和STAT3激活、GNAI2与IL6升高;IL6阻断抗体减少MDSC扩增和肿瘤数。CAC患者肿瘤组织GNAI1/GNAI3降低、GNAI2升高;公共数据库分析显示GNAI1/GNAI3低表达、GNAI2高表达与无复发生存期缩短显著相关。作者认为诱导GNAI1;3或阻断GNAI2和IL6可能用于CAC预防或治疗。

要点

  • GNAI1;3双敲除小鼠DSS后结肠炎更重,AOM+DSS后结肠肿瘤显著多于对照。
  • DKO小鼠肿瘤增加伴NF-κB和STAT3激活、GNAI2/IL6升高、CD4+DC和MDSC增多。
  • IL6阻断抗体减少DKO小鼠MDSC扩增和CAC诱导后的肿瘤数。

核心结论

  • GNAI1;3抑制小鼠DSS+AOM诱导的结肠肿瘤发展,而CD11c+细胞中GNAI2表达和CD4+/CD11b+DC中IL6表达可能促进该过程。
  • 作者认为诱导GNAI1;3或阻断GNAI2和IL6的策略可能用于CAC患者的预防或治疗。

研究设计与样本

  • B6;129野生型对照或Gnai1、Gnai2、Gnai3单/多基因敲除及CD11c+或上皮细胞条件性敲除Gnai2小鼠,给予DSS诱导结肠炎后给予AOM诱导癌变,部分小鼠给予IL6抗体。
  • 收集小鼠粪便以PCR分析微生物组,用流式细胞术分析脾和结肠组织的树突状细胞(DC)与髓源性抑制细胞(MDSC)。
  • 对结肠肿瘤组织、MDSC和小鼠胚胎成纤维细胞行免疫沉淀和免疫印迹,研究GNAI1、GNAI2、GNAI3表达及GNAI1/GNAI3与IL6信号通路蛋白的相互作用。
  • 用PrimeFlow分析结肠固有层CD11c+细胞Gnai2 mRNA表达,流式分析DC中IL6表达,ELISA检测血清和结肠组织细胞因子分泌。
  • 获取中国83例结直肠癌手术患者和美國35例CAC患者的结肠肿瘤及配对非肿瘤组织,行组织学、免疫印迹、免疫组化和/或RNA测序分析。

主要发现

  • GNAI1;3双敲除(DKO)小鼠给予DSS后结肠炎更严重,给予AOM+DSS后结肠肿瘤显著多于对照小鼠。
  • DKO小鼠肿瘤增加与粪便微生物组变化无关,而与NF-κB和STAT3激活、GNAI2/一氧化氮合酶2/IL6水平升高、CD4+DC和MDSC数量增加、CD8+DC数量减少相关。
  • DKO小鼠中IL6主要由CD4+/CD11b+DC而非CD8+DC产生。
  • 给DKO小鼠注射IL6阻断抗体减少MDSC扩增和CAC诱导后形成的肿瘤数。
  • CAC患者结肠肿瘤组织较正常组织GNAI1和GNAI3水平降低、GNAI2水平升高。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Interleukin 6 (IL6) and tumor necrosis factor contribute to the development of colitis-associated cancer (CAC). We investigated these signaling pathways and the involvement of G protein subunit alpha i1 (GNAI1), GNAI2, and GNAI3 in the development of CAC in mice and humans. METHODS: B6;129 wild-type (control) or mice with disruption of Gnai1, Gnai2, and/or Gnai3 or conditional disruption of Gnai2 in CD11c+ or epithelial cells were given dextran sulfate sodium (DSS) to induce colitis followed by azoxymethane (AOM) to induce carcinogenesis; some mice were given an antibody against IL6. Feces were collected from mice, and the compositions of microbiomes were analyzed by polymerase chain reactions. Dendritic cells (DCs) and myeloid-derived suppressor cells (MDSCs) isolated from spleen and colon tissues were analyzed by flow cytometry. We performed immunoprecipitation and immunoblot analyses of colon tumor tissues, MDSCs, and mouse embryonic fibroblasts to study the expression levels of GNAI1, GNAI2, and GNAI3 and the interactions of GNAI1 and GNAI3 with proteins in the IL6 signaling pathway. We analyzed the expression of Gnai2 messenger RNA by CD11c+ cells in the colonic lamina propria by PrimeFlow, expression of IL6 in DCs by flow cytometry, and secretion of cytokines in sera and colon tissues by enzyme-linked immunosorbent assay. We obtained colon tumor and matched nontumor tissues from 83 patients with colorectal cancer having surgery in China and 35 patients with CAC in the United States. Mouse and human colon tissues were analyzed by histology, immunoblot, immunohistochemistry, and/or RNA-sequencing analyses. RESULTS: GNAI1 and GNAI3 (GNAI1;3) double-knockout (DKO) mice developed more severe colitis after administration of DSS and significantly more colonic tumors than control mice after administration of AOM plus DSS. Development of increased tumors in DKO mice was not associated with changes in fecal microbiomes but was associated with activation of nuclear factor (NF) κB and signal transducer and activator of transcription (STAT) 3; increased levels of GNAI2, nitric oxide synthase 2, and IL6; increased numbers of CD4+ DCs and MDSCs; and decreased numbers of CD8+ DCs. IL6 was mainly produced by CD4+/CD11b+, but not CD8+, DCs in DKO mice. Injection of DKO mice with a blocking antibody against IL6 reduced the expansion of MDSCs and the number of tumors that developed after CAC induction. Incubation of MDSCs or mouse embryonic fibroblasts with IL6 induced activation of either NF-κB by a JAK2-TRAF6-TAK1-CHUK/IKKB signaling pathway or STAT3 by JAK2. This activation resulted in expression of GNAI2, IL6 signal transducer (IL6ST, also called GP130) and nitric oxide synthase 2, and expansion of MDSCs; the expression levels of these proteins and expansion of MDSCs were further increased by the absence of GNAI1;3 in cells and mice. Conditional disruption of Gnai2 in CD11c+ cells of DKO mice prevented activation of NF-κB and STAT3 and changes in numbers of DCs and MDSCs. Colon tumor tissues from patients with CAC had reduced levels of GNAI1 and GNAI3 and increased levels of GNAI2 compared with normal tissues. Further analysis of a public human colorectal tumor DNA microarray database (GSE39582) showed that low Gani1 and Gnai3 messenger RNA expression and high Gnai2 messenger RNA expression were significantly associated with decreased relapse-free survival. CONCLUSIONS: GNAI1;3 suppresses DSS-plus-AOM-induced colon tumor development in mice, whereas expression of GNAI2 in CD11c+ cells and IL6 in CD4+/CD11b+ DCs appears to promote these effects. Strategies to induce GNAI1;3, or block GNAI2 and IL6, might be developed for the prevention or therapy of CAC in patients.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Li ZW, Sun B, Gong T, et al. GNAI1 and GNAI3 Reduce Colitis-Associated Tumorigenesis in Mice by Blocking IL6 Signaling and Down-regulating Expression of GNAI2. Gastroenterology. 2019. PMID: 30836096. doi:10.1053/j.gastro.2019.02.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。